- Benzinga has examined prospects for many investor favorite stocks over the past week.
- Bullish calls included tech giants and a big oil leader.
- Bearish calls included biotechs and a recent IPO.
The escalating trade war with China continued to overshadow the markets in the past week. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
As usual, Benzinga continues to examine the prospects for many of the most popular stocks with investors. Here are just a few of this past week's most bullish and bearish posts that may be worth another look.
In "Bank Of America: Apple Is Still An Innovator," Jayson Derrick takes a look at why one top analyst feels that the Apple Inc. (NASDAQ: AAPL) era of innovation is far from over. Are investors guilty of underestimating the iPhone maker?
There seems to be significant expansion in the ways Alphabet Inc. (NASDAQ: GOOGL) can make ad money, according to Dave Royce's "Deutsche Bank More Bullish On Google With New 'Blockbuster' Ad Possibilities."
"3 Reasons Goldman Just Added Chevron To Its America's Conviction List" by Wayne Duggan shows why one top analyst thinks Chevron Corporation (NYSE: CVX) will be just fine after walking away from Anadarko.
Shanthi Rexaline's "Johnson & Johnson Analysts Laud Accelerating Pharma Business" reveals why analysts were impressed with the Johnson & Johnson (NYSE: JNJ) review of its pharmaceutical businesses.
For additional bullish calls, also have a look at DA Davidson Remains Bullish On Lyft, Despite Weak Uber IPO Raising Concerns Over Ride-Hailing Model and Cowen Likes Ralph Lauren On A Pullback Despite Looming Tariffs.
In Wayne Duggan's "Short Sellers Already Piling Into Uber," see why short interest in Uber Technologies Inc (NYSE: UBER) is already on the rise and likely to continue now that the company is in the red following its initial public offering.
ImmunoGen, Inc. (NASDAQ: IMGN) got bad news from the FDA about a cancer treatment, sending its shares lower last week. So says "Here's Why Small-Cap Biotech ImmunoGen Shares Are Tumbling" by Shanthi Rexaline.
"Why Array BioPharma Shares Fell Thursday" by Tanzeel Akhtar points out that comments from a sell-side analyst had Array BioPharma Inc. (NASDAQ: ARRY) shares in retreat ahead of this month's American Society of Clinical Oncology meeting.
Jayson Derrick's "Morgan Stanley Sees 80% Chance FedEx Trades Lower After Q4 Print" discusses why prior weak guidance from FedEx Corporation (NYSE: FDX) may carry over to the impending report.
Be sure to check out Analyst: Aurora Cannabis May Be 'Missing The Boat' In Beverages and Jim Cramer Advises His Viewers On Schlumberger, Applied Materials And More for additional bearish calls.
Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.
See more from Benzinga
- Notable Insider Buys This Past Week: Annaly Capital, MGM and More
- Bulls And Bears Of The Week: Boeing, Disney, Ford, Intel And More
- Barron's Picks And Pans: Community Health, GM, JB Hunt, Uber, UPS And More
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.